BIOMAT Database Logo BIOMAT Database Logo

[Glutamic acid decarboxylase autoantibodies (antiGAD-Ab) in patients with non-insulin dependent diabetes mellitus (NIDDM)]. 1998

E Martinka, and J Straková, and A Ocenásová, and D Pullmannová, and J Petrisková, and N Mácková, and L Sutarík, and P Galajda, and D Baláz, and J Kerný, and L Vladár, and M Mokán
I. interná klinika, JLF UK a MFN, Martin.

OBJECTIVE To assess the prevalence of markers of autoimmune destruction of pancreatic beta-cells in patients with non-insulin dependent diabetes mellitus (NIDDM). METHODS 127 hospitalized NIDDM patients subdivided to the following subgroups: non-obese with C-peptide < 0.3 nmol/l (NIDDM-(-)), non-obese with C-peptide > 0.3 nmol/l (NIDDM-(+)), obese with C-peptide < 0.3 nmol/l (NIDDM+(-)) and obese with C-peptide > 0.3 nmol/l (NIDDM2+). METHODS AND MEASURED PARAMETERS: Age, BMI, C-peptide, autoantibodies to glutamic acid decarboxylase (antiGAD-Ab), autoantibodies to islet cells (ICA), markers of specific cellular immunity CD4, CD8, CD19, CD4/CD8, CD4/CD45/RA+, CD4/CD45/RA-, NK (CD16+56), CD3/HLADR, organ specific/non-specific autoantibodies. RESULTS AntiGAD-Ab were positive in 5/15 (33.3%) NIDDM-(-), 1/32 (3.1%) NIDDM-(+), 2/9 (22.2%) NIDDM+(-) and in 3/71 (4.2%) NIDDM2+. The positivity of antiGAD-Ab in NIDDM-(-) and NIDDM+(-) was significantly higher (p < 0.05) than in NIDDM-(+) and NIDDM2+. CONCLUSIONS Some patients with manifestation of diabetes in older age initially classified and treated as having NIDDM may have in fact slowly evolving autoimmune insulin-dependent diabetes mellitus (LADA). These patients can be identified by measurement of antiGAD-Ab or other markers (ICA, IA-2) of autoimmune destruction of pancreatic beta-cells (AID). Moreover, in some patients both AID and insulin resistance may coexist in parallel.

UI MeSH Term Description Entries
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D005968 Glutamate Decarboxylase A pyridoxal-phosphate protein that catalyzes the alpha-decarboxylation of L-glutamic acid to form gamma-aminobutyric acid and carbon dioxide. The enzyme is found in bacteria and in invertebrate and vertebrate nervous systems. It is the rate-limiting enzyme in determining GAMMA-AMINOBUTYRIC ACID levels in normal nervous tissues. The brain enzyme also acts on L-cysteate, L-cysteine sulfinate, and L-aspartate. EC 4.1.1.15. Glutamate Carboxy-Lyase,Glutamic Acid Decarboxylase,Acid Decarboxylase, Glutamic,Carboxy-Lyase, Glutamate,Decarboxylase, Glutamate,Decarboxylase, Glutamic Acid,Glutamate Carboxy Lyase
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

E Martinka, and J Straková, and A Ocenásová, and D Pullmannová, and J Petrisková, and N Mácková, and L Sutarík, and P Galajda, and D Baláz, and J Kerný, and L Vladár, and M Mokán
Clinical evaluation of non-insulin-dependent diabetes mellitus patients with autoantibodies to glutamic acid decarboxylase.
October 1996, Journal of autoimmunity,
E Martinka, and J Straková, and A Ocenásová, and D Pullmannová, and J Petrisková, and N Mácková, and L Sutarík, and P Galajda, and D Baláz, and J Kerný, and L Vladár, and M Mokán
Autoantibodies against glutamic acid decarboxylase 65 in Japanese patients with insulin-dependent diabetes mellitus (IDDM).
February 1995, Journal of autoimmunity,
E Martinka, and J Straková, and A Ocenásová, and D Pullmannová, and J Petrisková, and N Mácková, and L Sutarík, and P Galajda, and D Baláz, and J Kerný, and L Vladár, and M Mokán
Glutamic acid decarboxylase autoantibodies in preclinical insulin-dependent diabetes.
October 1992, Proceedings of the National Academy of Sciences of the United States of America,
E Martinka, and J Straková, and A Ocenásová, and D Pullmannová, and J Petrisková, and N Mácková, and L Sutarík, and P Galajda, and D Baláz, and J Kerný, and L Vladár, and M Mokán
Glutamic acid decarboxylase in insulin-dependent diabetes mellitus.
July 1992, Diabetes/metabolism reviews,
E Martinka, and J Straková, and A Ocenásová, and D Pullmannová, and J Petrisková, and N Mácková, and L Sutarík, and P Galajda, and D Baláz, and J Kerný, and L Vladár, and M Mokán
Quantitative analysis of islet glutamic acid decarboxylase p64 autoantibodies in insulin-dependent diabetes mellitus.
January 1992, Autoimmunity,
E Martinka, and J Straková, and A Ocenásová, and D Pullmannová, and J Petrisková, and N Mácková, and L Sutarík, and P Galajda, and D Baláz, and J Kerný, and L Vladár, and M Mokán
HLA and glutamic acid decarboxylase in human insulin-dependent diabetes mellitus.
March 1996, Diabetic medicine : a journal of the British Diabetic Association,
E Martinka, and J Straková, and A Ocenásová, and D Pullmannová, and J Petrisková, and N Mácková, and L Sutarík, and P Galajda, and D Baláz, and J Kerný, and L Vladár, and M Mokán
Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity.
October 1997, Neurology,
E Martinka, and J Straková, and A Ocenásová, and D Pullmannová, and J Petrisková, and N Mácková, and L Sutarík, and P Galajda, and D Baláz, and J Kerný, and L Vladár, and M Mokán
Insulin requirement in elderly patients with non-insulin dependent diabetes mellitus (NIDDM).
January 1989, Aging (Milan, Italy),
E Martinka, and J Straková, and A Ocenásová, and D Pullmannová, and J Petrisková, and N Mácková, and L Sutarík, and P Galajda, and D Baláz, and J Kerný, and L Vladár, and M Mokán
Insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM).
January 1988, Diabetes research and clinical practice,
E Martinka, and J Straková, and A Ocenásová, and D Pullmannová, and J Petrisková, and N Mácková, and L Sutarík, and P Galajda, and D Baláz, and J Kerný, and L Vladár, and M Mokán
Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus.
July 1994, Lancet (London, England),
Copied contents to your clipboard!